 Casey Greene
Concepts (414)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computational Biology | 32 | 2025 | 588 | 6.150 |
Why?
| | Gene Expression Profiling | 23 | 2025 | 1696 | 4.310 |
Why?
| | Software | 17 | 2025 | 612 | 3.180 |
Why?
| | Machine Learning | 18 | 2024 | 418 | 3.150 |
Why?
| | Single-Cell Analysis | 8 | 2025 | 267 | 3.110 |
Why?
| | Genomics | 18 | 2025 | 716 | 2.830 |
Why?
| | Transcriptome | 20 | 2024 | 875 | 2.690 |
Why?
| | Algorithms | 18 | 2025 | 1626 | 2.370 |
Why?
| | Gene Regulatory Networks | 10 | 2024 | 279 | 2.360 |
Why?
| | Information Dissemination | 6 | 2020 | 206 | 2.300 |
Why?
| | Epistasis, Genetic | 6 | 2023 | 69 | 1.760 |
Why?
| | Neoplasms | 12 | 2022 | 2429 | 1.680 |
Why?
| | Biomedical Research | 5 | 2025 | 654 | 1.670 |
Why?
| | Data Mining | 5 | 2018 | 107 | 1.650 |
Why?
| | Pseudomonas aeruginosa | 7 | 2024 | 343 | 1.640 |
Why?
| | Viral Vaccines | 2 | 2023 | 93 | 1.540 |
Why?
| | Sequence Analysis, RNA | 7 | 2025 | 422 | 1.510 |
Why?
| | Rare Diseases | 2 | 2023 | 102 | 1.410 |
Why?
| | Databases, Genetic | 13 | 2022 | 226 | 1.370 |
Why?
| | Ovarian Neoplasms | 7 | 2025 | 484 | 1.310 |
Why?
| | Gene Expression | 4 | 2023 | 1477 | 1.170 |
Why?
| | Research Personnel | 2 | 2020 | 161 | 1.160 |
Why?
| | Genome-Wide Association Study | 10 | 2021 | 1334 | 1.100 |
Why?
| | Artificial Intelligence | 4 | 2024 | 233 | 1.000 |
Why?
| | Humans | 102 | 2025 | 129078 | 0.990 |
Why?
| | Natural Language Processing | 2 | 2024 | 92 | 0.980 |
Why?
| | Peer Review, Research | 2 | 2022 | 40 | 0.940 |
Why?
| | Nonlinear Dynamics | 2 | 2023 | 88 | 0.930 |
Why?
| | Journalism | 1 | 2024 | 7 | 0.910 |
Why?
| | Direct-To-Consumer Screening and Testing | 1 | 2024 | 1 | 0.910 |
Why?
| | Breeding | 1 | 2024 | 62 | 0.890 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2023 | 28 | 0.860 |
Why?
| | User-Computer Interface | 4 | 2023 | 147 | 0.790 |
Why?
| | Societies, Scientific | 1 | 2021 | 47 | 0.740 |
Why?
| | Genetic Testing | 1 | 2024 | 425 | 0.720 |
Why?
| | Metadata | 1 | 2020 | 7 | 0.720 |
Why?
| | Neurofibromin 1 | 2 | 2019 | 24 | 0.710 |
Why?
| | Data Compression | 1 | 2020 | 5 | 0.690 |
Why?
| | Guidelines as Topic | 1 | 2022 | 260 | 0.670 |
Why?
| | Computer Simulation | 7 | 2025 | 943 | 0.650 |
Why?
| | Precision Medicine | 5 | 2024 | 386 | 0.640 |
Why?
| | Computer Security | 1 | 2019 | 19 | 0.640 |
Why?
| | Genetic Association Studies | 3 | 2016 | 356 | 0.640 |
Why?
| | Language | 1 | 2022 | 283 | 0.630 |
Why?
| | Confidentiality | 1 | 2019 | 70 | 0.620 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 485 | 0.620 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 171 | 0.610 |
Why?
| | Scholarly Communication | 1 | 2018 | 2 | 0.600 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2025 | 593 | 0.600 |
Why?
| | Databases, Bibliographic | 1 | 2018 | 30 | 0.590 |
Why?
| | ras Proteins | 2 | 2019 | 150 | 0.590 |
Why?
| | Probability | 3 | 2024 | 313 | 0.570 |
Why?
| | Cystadenocarcinoma, Serous | 3 | 2025 | 68 | 0.570 |
Why?
| | Access to Information | 1 | 2018 | 47 | 0.570 |
Why?
| | Biomedical Technology | 1 | 2018 | 39 | 0.570 |
Why?
| | Glioblastoma | 2 | 2019 | 313 | 0.560 |
Why?
| | Disease | 3 | 2018 | 95 | 0.560 |
Why?
| | Gene Silencing | 2 | 2018 | 181 | 0.550 |
Why?
| | Models, Biological | 3 | 2020 | 1704 | 0.540 |
Why?
| | alpha-Synuclein | 1 | 2017 | 30 | 0.540 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 132 | 0.530 |
Why?
| | Parasites | 1 | 2017 | 39 | 0.530 |
Why?
| | Genome, Human | 6 | 2018 | 393 | 0.520 |
Why?
| | Systems Biology | 3 | 2018 | 59 | 0.510 |
Why?
| | Models, Genetic | 5 | 2019 | 588 | 0.510 |
Why?
| | Workflow | 1 | 2017 | 150 | 0.510 |
Why?
| | Gene Ontology | 5 | 2020 | 49 | 0.510 |
Why?
| | MicroRNAs | 1 | 2022 | 669 | 0.500 |
Why?
| | Research | 1 | 2018 | 413 | 0.490 |
Why?
| | Quantitative Trait, Heritable | 1 | 2016 | 119 | 0.480 |
Why?
| | Unsupervised Machine Learning | 4 | 2024 | 16 | 0.480 |
Why?
| | Neurodegenerative Diseases | 1 | 2017 | 108 | 0.480 |
Why?
| | Protein Interaction Maps | 1 | 2015 | 43 | 0.480 |
Why?
| | Bacterial Proteins | 2 | 2020 | 829 | 0.480 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 596 | 0.450 |
Why?
| | Internet | 5 | 2023 | 616 | 0.450 |
Why?
| | Authorship | 2 | 2024 | 44 | 0.440 |
Why?
| | Models, Theoretical | 1 | 2017 | 550 | 0.430 |
Why?
| | Bayes Theorem | 5 | 2018 | 368 | 0.430 |
Why?
| | RNA, Untranslated | 1 | 2014 | 114 | 0.400 |
Why?
| | Cluster Analysis | 3 | 2024 | 479 | 0.380 |
Why?
| | Microbiota | 2 | 2017 | 724 | 0.370 |
Why?
| | Drosophila melanogaster | 5 | 2019 | 217 | 0.370 |
Why?
| | Pandemics | 5 | 2023 | 1516 | 0.370 |
Why?
| | Signal Transduction | 8 | 2020 | 4867 | 0.360 |
Why?
| | Bibliometrics | 2 | 2024 | 53 | 0.360 |
Why?
| | Writing | 2 | 2024 | 92 | 0.350 |
Why?
| | Publishing | 2 | 2024 | 139 | 0.350 |
Why?
| | Databases, Factual | 2 | 2018 | 1289 | 0.340 |
Why?
| | Embryonic Development | 3 | 2020 | 118 | 0.330 |
Why?
| | Terminology as Topic | 3 | 2022 | 204 | 0.330 |
Why?
| | Molecular Sequence Annotation | 5 | 2023 | 88 | 0.330 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2010 | 68 | 0.320 |
Why?
| | Scleroderma, Systemic | 3 | 2017 | 109 | 0.310 |
Why?
| | Supervised Machine Learning | 2 | 2020 | 14 | 0.310 |
Why?
| | Genome | 2 | 2019 | 276 | 0.310 |
Why?
| | Female | 22 | 2025 | 68274 | 0.310 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2071 | 0.280 |
Why?
| | Animals | 19 | 2025 | 34708 | 0.280 |
Why?
| | Betacoronavirus | 2 | 2020 | 266 | 0.280 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 799 | 0.280 |
Why?
| | Drosophila Proteins | 2 | 2019 | 189 | 0.260 |
Why?
| | Proteomics | 4 | 2021 | 988 | 0.260 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 264 | 0.250 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 337 | 0.240 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 361 | 0.240 |
Why?
| | Coronavirus Infections | 2 | 2020 | 355 | 0.240 |
Why?
| | Publications | 2 | 2022 | 42 | 0.230 |
Why?
| | Reproducibility of Results | 6 | 2021 | 3047 | 0.230 |
Why?
| | Mice | 12 | 2025 | 16583 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2021 | 2273 | 0.220 |
Why?
| | Sexism | 1 | 2024 | 54 | 0.220 |
Why?
| | Cell Line, Tumor | 4 | 2019 | 3114 | 0.220 |
Why?
| | Breast Neoplasms | 2 | 2015 | 2116 | 0.210 |
Why?
| | Science | 1 | 2024 | 53 | 0.210 |
Why?
| | Cystic Fibrosis | 2 | 2024 | 1061 | 0.210 |
Why?
| | Causality | 1 | 2023 | 115 | 0.210 |
Why?
| | Dogs | 1 | 2024 | 372 | 0.210 |
Why?
| | Vaccines, Subunit | 1 | 2023 | 47 | 0.200 |
Why?
| | Pedigree | 1 | 2024 | 491 | 0.200 |
Why?
| | Male | 16 | 2025 | 63248 | 0.200 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2019 | 225 | 0.200 |
Why?
| | Sample Size | 1 | 2022 | 117 | 0.200 |
Why?
| | Mushroom Bodies | 2 | 2019 | 6 | 0.200 |
Why?
| | Hedgehog Proteins | 2 | 2021 | 187 | 0.190 |
Why?
| | Pseudomonas Infections | 1 | 2024 | 217 | 0.190 |
Why?
| | Periodicals as Topic | 1 | 2024 | 209 | 0.190 |
Why?
| | High-Throughput Screening Assays | 2 | 2014 | 134 | 0.180 |
Why?
| | Quality Control | 1 | 2021 | 155 | 0.180 |
Why?
| | Neoplasm Grading | 4 | 2025 | 278 | 0.180 |
Why?
| | Electronic Health Records | 3 | 2018 | 971 | 0.180 |
Why?
| | ADAM10 Protein | 1 | 2021 | 30 | 0.180 |
Why?
| | Cooperative Behavior | 2 | 2021 | 428 | 0.180 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 878 | 0.180 |
Why?
| | Bone Development | 1 | 2021 | 48 | 0.180 |
Why?
| | Gamma Rays | 1 | 2021 | 52 | 0.180 |
Why?
| | Fibrosis | 2 | 2021 | 518 | 0.180 |
Why?
| | Alzheimer Disease | 2 | 2017 | 511 | 0.180 |
Why?
| | Mutation | 5 | 2025 | 3679 | 0.170 |
Why?
| | Linear Models | 1 | 2023 | 818 | 0.170 |
Why?
| | Cystadenoma, Serous | 1 | 2020 | 17 | 0.170 |
Why?
| | Privacy | 1 | 2020 | 33 | 0.170 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 78 | 0.170 |
Why?
| | Medical Informatics | 1 | 2021 | 99 | 0.170 |
Why?
| | Organ Specificity | 3 | 2017 | 296 | 0.170 |
Why?
| | Hemerythrin | 1 | 2020 | 1 | 0.170 |
Why?
| | Bone Diseases | 1 | 2021 | 60 | 0.170 |
Why?
| | Histone Code | 1 | 2020 | 31 | 0.170 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2020 | 1318 | 0.170 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 86 | 0.170 |
Why?
| | Systems Integration | 2 | 2017 | 40 | 0.170 |
Why?
| | Radiation Injuries | 1 | 2021 | 139 | 0.160 |
Why?
| | Neurofibromatosis 1 | 1 | 2020 | 44 | 0.160 |
Why?
| | Radiosurgery | 1 | 2022 | 316 | 0.160 |
Why?
| | Phenotype | 4 | 2021 | 3062 | 0.160 |
Why?
| | Genetic Fitness | 1 | 2020 | 54 | 0.160 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 190 | 0.160 |
Why?
| | Cerebellar Neoplasms | 1 | 2021 | 150 | 0.160 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 290 | 0.160 |
Why?
| | Exons | 1 | 2020 | 332 | 0.160 |
Why?
| | Biofilms | 2 | 2019 | 248 | 0.160 |
Why?
| | Base Sequence | 1 | 2022 | 2157 | 0.160 |
Why?
| | Medulloblastoma | 1 | 2021 | 192 | 0.160 |
Why?
| | DNA Repair | 2 | 2011 | 208 | 0.160 |
Why?
| | Cell Hypoxia | 1 | 2020 | 238 | 0.150 |
Why?
| | Computer Communication Networks | 1 | 2018 | 32 | 0.150 |
Why?
| | Gene Expression Regulation | 3 | 2018 | 2523 | 0.150 |
Why?
| | Proteins | 2 | 2016 | 945 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2019 | 510 | 0.150 |
Why?
| | Down Syndrome | 1 | 2025 | 454 | 0.150 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1174 | 0.150 |
Why?
| | Pseudomonas fluorescens | 1 | 2018 | 4 | 0.150 |
Why?
| | Hypertension | 2 | 2019 | 1237 | 0.150 |
Why?
| | Sex Factors | 1 | 2024 | 1950 | 0.150 |
Why?
| | Alternative Splicing | 1 | 2020 | 216 | 0.150 |
Why?
| | Recombinational DNA Repair | 1 | 2018 | 12 | 0.150 |
Why?
| | Multiple Myeloma | 1 | 2019 | 120 | 0.150 |
Why?
| | Atlases as Topic | 1 | 2018 | 10 | 0.150 |
Why?
| | Cyclic GMP | 1 | 2018 | 85 | 0.150 |
Why?
| | Pennsylvania | 1 | 2018 | 105 | 0.150 |
Why?
| | Bone and Bones | 1 | 2021 | 297 | 0.150 |
Why?
| | Glomerulonephritis | 1 | 2018 | 46 | 0.150 |
Why?
| | Immunity, Cellular | 1 | 2019 | 267 | 0.140 |
Why?
| | False Positive Reactions | 1 | 2018 | 115 | 0.140 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 147 | 0.140 |
Why?
| | Public Sector | 1 | 2017 | 18 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 527 | 0.140 |
Why?
| | Starvation | 1 | 2017 | 22 | 0.140 |
Why?
| | Phosphoproteins | 1 | 2019 | 326 | 0.140 |
Why?
| | Trans-Activators | 1 | 2020 | 387 | 0.140 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 635 | 0.140 |
Why?
| | Drug Design | 1 | 2018 | 156 | 0.140 |
Why?
| | Metabolic Networks and Pathways | 1 | 2018 | 176 | 0.140 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 428 | 0.140 |
Why?
| | Information Storage and Retrieval | 1 | 2017 | 106 | 0.130 |
Why?
| | Body Mass Index | 1 | 2025 | 2250 | 0.130 |
Why?
| | Data Collection | 1 | 2019 | 652 | 0.130 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 282 | 0.130 |
Why?
| | Amygdala | 1 | 2017 | 182 | 0.130 |
Why?
| | Genome, Microbial | 1 | 2016 | 7 | 0.130 |
Why?
| | Phylogeny | 1 | 2020 | 844 | 0.130 |
Why?
| | Memory | 1 | 2017 | 231 | 0.130 |
Why?
| | Microbial Consortia | 1 | 2016 | 19 | 0.130 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2015 | 18 | 0.130 |
Why?
| | Drug Repositioning | 1 | 2015 | 24 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2018 | 772 | 0.120 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2018 | 321 | 0.120 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 487 | 0.120 |
Why?
| | Structure-Activity Relationship | 1 | 2016 | 540 | 0.120 |
Why?
| | Research Design | 1 | 2021 | 1039 | 0.120 |
Why?
| | Toxicology | 1 | 2015 | 42 | 0.120 |
Why?
| | Search Engine | 1 | 2015 | 9 | 0.120 |
Why?
| | Blood Pressure | 2 | 2019 | 1746 | 0.120 |
Why?
| | Social Behavior | 1 | 2017 | 288 | 0.120 |
Why?
| | Knowledge Bases | 1 | 2015 | 22 | 0.120 |
Why?
| | RNA | 4 | 2024 | 877 | 0.120 |
Why?
| | Metabolome | 1 | 2017 | 316 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2021 | 1102 | 0.120 |
Why?
| | Decision Support Techniques | 1 | 2018 | 387 | 0.110 |
Why?
| | Prognosis | 3 | 2021 | 3793 | 0.110 |
Why?
| | Circadian Rhythm | 1 | 2017 | 402 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2015 | 170 | 0.110 |
Why?
| | Genes | 3 | 2013 | 227 | 0.110 |
Why?
| | Hospital Mortality | 1 | 2018 | 853 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1367 | 0.110 |
Why?
| | Proteome | 1 | 2017 | 423 | 0.110 |
Why?
| | Biological Phenomena | 1 | 2013 | 4 | 0.110 |
Why?
| | Macrophages | 1 | 2021 | 1456 | 0.110 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2015 | 246 | 0.110 |
Why?
| | Intensive Care Units | 1 | 2018 | 733 | 0.110 |
Why?
| | Podocytes | 1 | 2013 | 47 | 0.100 |
Why?
| | Sequence Analysis, DNA | 3 | 2025 | 778 | 0.100 |
Why?
| | Length of Stay | 1 | 2018 | 1128 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1842 | 0.100 |
Why?
| | Brain | 1 | 2024 | 2604 | 0.100 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 423 | 0.100 |
Why?
| | Cell Lineage | 1 | 2013 | 333 | 0.090 |
Why?
| | Obesity | 1 | 2025 | 2847 | 0.090 |
Why?
| | Survival Analysis | 1 | 2015 | 1283 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2017 | 642 | 0.090 |
Why?
| | Cell Line | 2 | 2017 | 2762 | 0.090 |
Why?
| | Decision Making | 1 | 2018 | 837 | 0.090 |
Why?
| | Pediatrics | 1 | 2019 | 1061 | 0.090 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1138 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2018 | 896 | 0.090 |
Why?
| | Bias | 1 | 2012 | 196 | 0.090 |
Why?
| | Microglia | 2 | 2024 | 228 | 0.090 |
Why?
| | Knowledge | 1 | 2010 | 49 | 0.090 |
Why?
| | Multifactor Dimensionality Reduction | 1 | 2010 | 2 | 0.090 |
Why?
| | Models, Statistical | 3 | 2020 | 627 | 0.080 |
Why?
| | Parkinson Disease | 1 | 2015 | 410 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2013 | 366 | 0.080 |
Why?
| | Memory, Long-Term | 2 | 2019 | 12 | 0.080 |
Why?
| | Transcription Factors | 1 | 2017 | 1636 | 0.080 |
Why?
| | Aged | 7 | 2025 | 22068 | 0.080 |
Why?
| | Rats | 3 | 2013 | 5254 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1264 | 0.080 |
Why?
| | Geography | 1 | 2009 | 185 | 0.080 |
Why?
| | Child | 4 | 2021 | 20860 | 0.080 |
Why?
| | Adult | 6 | 2025 | 35423 | 0.080 |
Why?
| | Biopsy | 3 | 2018 | 1093 | 0.080 |
Why?
| | Gene Frequency | 1 | 2009 | 503 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5365 | 0.070 |
Why?
| | Middle Aged | 8 | 2025 | 31024 | 0.070 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 561 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2015 | 4063 | 0.070 |
Why?
| | United States | 2 | 2021 | 13992 | 0.070 |
Why?
| | Multifactorial Inheritance | 1 | 2008 | 148 | 0.070 |
Why?
| | Alleles | 1 | 2009 | 847 | 0.060 |
Why?
| | Terminal Repeat Sequences | 1 | 2006 | 16 | 0.060 |
Why?
| | Cytokines | 2 | 2018 | 1997 | 0.060 |
Why?
| | Retroelements | 1 | 2006 | 45 | 0.060 |
Why?
| | Bone Density | 2 | 2021 | 470 | 0.060 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2025 | 36 | 0.060 |
Why?
| | Pilot Projects | 2 | 2022 | 1548 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2019 | 10256 | 0.060 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2025 | 39 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2009 | 3336 | 0.060 |
Why?
| | Europe | 1 | 2025 | 366 | 0.060 |
Why?
| | Culture Media | 1 | 2024 | 168 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 101 | 0.050 |
Why?
| | Metals | 1 | 2024 | 126 | 0.050 |
Why?
| | Microarray Analysis | 1 | 2023 | 122 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 521 | 0.050 |
Why?
| | Astrocytes | 1 | 2024 | 190 | 0.050 |
Why?
| | Smoking | 1 | 2010 | 1501 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5282 | 0.050 |
Why?
| | Budgets | 1 | 2021 | 14 | 0.050 |
Why?
| | Sputum | 1 | 2024 | 309 | 0.050 |
Why?
| | Interdisciplinary Research | 1 | 2021 | 26 | 0.050 |
Why?
| | Gene Library | 1 | 2021 | 118 | 0.050 |
Why?
| | Ephrin-B2 | 1 | 2021 | 50 | 0.040 |
Why?
| | Neurofibroma | 1 | 2020 | 3 | 0.040 |
Why?
| | Gene Editing | 1 | 2021 | 66 | 0.040 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2020 | 8 | 0.040 |
Why?
| | Neurofibroma, Plexiform | 1 | 2020 | 8 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2025 | 7063 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2021 | 194 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 336 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 383 | 0.040 |
Why?
| | Osteoblasts | 1 | 2021 | 118 | 0.040 |
Why?
| | Antigens, CD20 | 1 | 2019 | 28 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 83 | 0.040 |
Why?
| | Data Accuracy | 1 | 2020 | 59 | 0.040 |
Why?
| | Candida albicans | 1 | 2019 | 53 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2020 | 115 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2020 | 67 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2021 | 505 | 0.040 |
Why?
| | Manuscripts, Medical as Topic | 1 | 2019 | 5 | 0.040 |
Why?
| | Young Adult | 3 | 2021 | 12310 | 0.040 |
Why?
| | Genome, Fungal | 1 | 2019 | 33 | 0.040 |
Why?
| | Mentoring | 1 | 2021 | 120 | 0.040 |
Why?
| | Reward | 1 | 2021 | 238 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 929 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2019 | 74 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 63 | 0.040 |
Why?
| | Locomotion | 1 | 2019 | 98 | 0.040 |
Why?
| | Osteogenesis | 1 | 2021 | 190 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2019 | 136 | 0.040 |
Why?
| | Wilms Tumor | 1 | 2019 | 77 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 295 | 0.040 |
Why?
| | Neuroblastoma | 1 | 2019 | 152 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2021 | 355 | 0.040 |
Why?
| | Sarcoma, Ewing | 1 | 2019 | 86 | 0.040 |
Why?
| | Genes, Neoplasm | 1 | 2018 | 20 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 203 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 812 | 0.040 |
Why?
| | Two-Hybrid System Techniques | 1 | 2018 | 56 | 0.040 |
Why?
| | Loss of Heterozygosity | 1 | 2018 | 45 | 0.040 |
Why?
| | Pentose Phosphate Pathway | 1 | 2018 | 49 | 0.040 |
Why?
| | Nephrotic Syndrome | 1 | 2018 | 28 | 0.040 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2018 | 23 | 0.040 |
Why?
| | Monocytes | 1 | 2021 | 553 | 0.040 |
Why?
| | Mobile Applications | 1 | 2020 | 158 | 0.040 |
Why?
| | Acid Phosphatase | 1 | 2017 | 19 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2019 | 305 | 0.040 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 106 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 448 | 0.040 |
Why?
| | Mouth | 1 | 2017 | 81 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 382 | 0.040 |
Why?
| | Kidney Tubules | 1 | 2018 | 114 | 0.040 |
Why?
| | Patient Care Planning | 1 | 2018 | 152 | 0.030 |
Why?
| | Isoenzymes | 1 | 2018 | 303 | 0.030 |
Why?
| | GTPase-Activating Proteins | 1 | 2017 | 82 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2017 | 88 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2018 | 127 | 0.030 |
Why?
| | Chromatin | 1 | 2021 | 471 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 83 | 0.030 |
Why?
| | Motivation | 1 | 2021 | 541 | 0.030 |
Why?
| | Databases, Protein | 1 | 2016 | 61 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1013 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 935 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1886 | 0.030 |
Why?
| | Saliva | 1 | 2017 | 204 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 1195 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2021 | 644 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 63 | 0.030 |
Why?
| | Biopsy, Fine-Needle | 1 | 2016 | 66 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2018 | 361 | 0.030 |
Why?
| | Genetic Loci | 1 | 2017 | 274 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 662 | 0.030 |
Why?
| | Blood Proteins | 1 | 2017 | 233 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 313 | 0.030 |
Why?
| | DNA Damage | 1 | 2018 | 377 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2017 | 300 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 460 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2018 | 251 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 750 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 9804 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 833 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1966 | 0.030 |
Why?
| | Oxygen | 1 | 2020 | 913 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1005 | 0.030 |
Why?
| | Esophagus | 1 | 2017 | 253 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1409 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2016 | 579 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 543 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 817 | 0.030 |
Why?
| | Aging | 1 | 2024 | 1773 | 0.030 |
Why?
| | Colorado | 1 | 2024 | 4445 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 873 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 608 | 0.030 |
Why?
| | Heart Rate | 1 | 2017 | 808 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2344 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2670 | 0.030 |
Why?
| | Regression Analysis | 1 | 2015 | 987 | 0.030 |
Why?
| | Support Vector Machine | 1 | 2013 | 37 | 0.030 |
Why?
| | Organogenesis | 1 | 2013 | 57 | 0.030 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 169 | 0.020 |
Why?
| | Nanotechnology | 1 | 2013 | 119 | 0.020 |
Why?
| | Computer Graphics | 1 | 2012 | 42 | 0.020 |
Why?
| | Risk | 1 | 2015 | 867 | 0.020 |
Why?
| | Skin | 1 | 2017 | 737 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 20241 | 0.020 |
Why?
| | Apoptosis | 1 | 2021 | 2485 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 370 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 493 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2018 | 2702 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 935 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5036 | 0.020 |
Why?
| | Caenorhabditis elegans | 1 | 2013 | 301 | 0.020 |
Why?
| | Zebrafish Proteins | 1 | 2012 | 258 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 3999 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 400 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 448 | 0.020 |
Why?
| | Curriculum | 1 | 2015 | 925 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 996 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6579 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 10462 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1858 | 0.020 |
Why?
| | Lung | 1 | 2017 | 3925 | 0.010 |
Why?
| | Inflammation | 1 | 2015 | 2696 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2357 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 14562 | 0.010 |
Why?
|
|
Greene's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|